Proassurance Corp Dossier - Source-backed chat

Proassurance Corp

PRANYSE

SectorFinancials

IndustryProperty and Casualty Insurance

Beta (adjusted)0.36

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $25.00Price as of 25 Jun 2026

Data confidenceNot applicable

Market Cap $1.3B

Enterprise Value $1.7B

Shares Outstanding 52M diluted

Next Earnings Date3 Nov 2026

Last ex-dividend28 Mar 2023

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ProAssurance Corporation (PRA) is navigating a challenging underwriting cycle characterized by elevated claims severity and social inflation in its core Medical Professional Liability (MPL) line. While management's disciplined 'rate over volume' strategy has driven cumulative rate increases of over 80% since 2018 and returned the Specialty P&C segment to full-year underwriting profitability in 2025 (98.3% combined ratio), near-term pressures remain evident. The Q1 2026 consolidated combined ratio of 109.9% highlights ongoing headwinds. With the stock trading near its consensus price target of $25.00 and a premium trailing P/E multiple relative to peers, the risk-reward profile is balanced, supporting a Hold recommendation as the market monitors the sustainability of its margin expansion.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$25.00

Mean target$25.00

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$20.0020%

Deteriorating claims frequency and severity, driven by nuclear verdicts in the U.S. healthcare sector, outpace pricing actions. Hardening reinsurance markets force the company to retain more risk or pay higher premiums, squeezing underwriting margins. Adverse prior-year reserve development emerges, requiring reserve strengthening. The consolidated combined ratio remains elevated above 110%, leading to earnings downgrades and multiple contraction.

Base CaseCentral scenario

$25.0050%

Matches the consensus mean

ProAssurance maintains strict underwriting discipline, prioritizing rate adequacy over premium volume. The Specialty P&C segment combined ratio hovers around 100-104% due to persistent social inflation, while net investment income remains a stable earnings driver. Revenue remains flat to slightly down as the company walks away from underpriced business. The stock trades in line with its historical peer group multiples, reflecting a slow but steady recovery path.

Bull CaseUpside scenario

$25.0030%

The operational turnaround accelerates as cumulative premium rate increases outpace loss cost trends. The Specialty P&C segment consistently achieves a combined ratio below 100%, supported by favorable prior-year reserve development and operational synergies from the NORCAL integration. Higher yields on the fixed-income portfolio continue to boost net investment income, offsetting flat premium growth. Valuation expands toward historical book value multiples as return on equity (ROE) normalizes toward 7-8%.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong underwriting discipline with a clear focus on 'rate over volume' to restore core profitability.
Robust investment portfolio providing a stable cushion, benefiting from higher reinvestment yields.
Strong capital position with AM Best affirming an 'A' (Excellent) rating and assessing the balance sheet as 'strongest' in July 2025.
Completed integration of the NORCAL acquisition, driving operational synergies and centralized claims management.

Key Investment Risks

Social inflation and rising litigation costs leading to elevated claims severity in healthcare professional liability.
Hardening reinsurance markets increasing the cost of risk transfer or forcing higher risk retention.
Potential for adverse prior-year reserve development if historical reserving assumptions prove inadequate.
Highly competitive market conditions in medical professional liability and workers' compensation lines.

Thesis Invalidation Triggers

A sustained spike in the consolidated combined ratio above 112% over multiple quarters.
Significant adverse prior-year reserve development exceeding $15 million in a single quarter.
A downgrade of the company's financial strength rating by AM Best below 'A'.
A sharp decline in net investment income driven by rapid interest rate cuts or investment portfolio impairments.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.